Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.
To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Latest Media Coverage
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Browse the archive
Financial Times
Drug wars: how AstraZeneca overtook GSK in UK pharma
By 2022, AstraZeneca is expected to return to the ranks of the world’s top 10 pharma companies thanks to its new blockbuster drugs, according to data provider…
Handelsblatt
Corona drug search: The pharmaceutical industry sets new priorities
The British analysis company Evaluate Pharma, for example, estimates that the number of interrupted and delayed clinical studies has increased by a factor of 15 compared…
The Pharma Letter
EMA validates tafasitamab regulatory submission
he sell-side expects tafasitamab to generate 2024 revenue of $661 million, according to EvaluatePharma consensus forecasts.
PMLive
FDA gives Roche’s Tecentriq green light for first-line NSCLC
That initial approval in NSCLC helped Keytruda to become the forecasted highest selling drug globally by 2024, with Evaluate Pharma predicting Merck/MSD’s drug will reach…
PMLive
Merck’s Keytruda hits the mark in triple negative breast cancer
Keytruda remains dominant in the anti-PD-1/L1 category, with EvaluatePharma forecasting that sales of the drug will reach $24.3bn in 2026.
Pharmaphorum
FDA clears Lilly’s Retevmo for RET-positive lung, thyroid
EvaluatePharma has said that selpercatinib could become a $500 million-plus product by 2024.
The Pharma Letter
Look back at pharma news in the week to May 8, 2020
Large-scale M&A might be off the table during the COVID-19 pandemic, but Menarini proved last Monday that the day-to-day business of smaller transactions continues,…
The Pharma Letter
Look back at pharma news in the week to May 1, 2020
Evaluate Vantage has been tracking notable COVID-19 announcements, and it is clear that the pandemic news flow is showing no sign of slowing.
El Pais
The Covid-19 vaccine will need the capacity of the big four manufacturers
The biopharmaceutical industry is working at full speed to find a vaccine against the Covid-19 pandemic. There are already almost 89 R&D projects to find that…
El Global
Covid-19: 230 clinical trials with 196,230 patients worldwide
Efforts to research or develop a drug that helps fight SARS-CoV-2 are titanic. And so shows a report recently published by the consultant Evaluate Pharma. This study…
